… good-PS patients with EGFR mutation-positive advanced NSCLC … or increased incidence of
erlotinib-related toxicities. … specific reasons for poor PS were not clarified in the current study. …

… Erlotinib plus bevacizumab, ramucirumab plus erlotinib, and … reported in Asia, with non-small-cell
lung cancer (NSCLC) as … out a well-designed phase III, multicenter RCT, which makes …

… of erlotinib as a first-line treatment for EGFR mutation-positive … of ramucirumab plus erlotinib
with that of erlotinib alone in … is a multicenter, randomized, double-blind, phase 3 clinical trial …

… , six patients had previously treated stable brain metastases. … in elderly patients with
EGFR mutation-positive NSCLC. The … plus gefitinib, or erlotinib plus ramucirumab [25,26,27,28,29]. …

… first-line erlotinib in Asian population with EGFR mutation-positive … RELAY trial is a phase
III double-blind study that assessed the role of ramucirumab or placebo in addition to erlotinib …

… ) or (VEGF inhibitor or bevacizumab or ramucirumab or VEGFR inhibitor or anti-… metastatic
EGFR mutation-positive non-small-cell lung cancer (FURLONG): A multicentre, double-blind…

… , treatment of advanced or metastatic non-small cell lung … with the first- or second-generation
TKI erlotinib, gefitinib or … as bevacizumab (NCT04181060) or ramucirumab 19 in this setting, …

… of erlotinib and ramucirumab versus erlotinib alone in the … Patients with brain metastases
were excluded from the study. … mutation-positive NSCLC who received sequential treatment …

… the feasibility of combining erlotinib and angiogenesis for … pretreated patients with EGFR
mutation-positive lung cancer was … This study is currently enrolling patients with metastatic EGFR…

… RELAY trial, a large global, placebo-controlled, double-blind trial, evaluated the effects of
erlotinib plus ramucirumab versus erlotinib plus placebo in 449 patients with metastatic NSCLC…